Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients

NCT02033317 is registered in ClinicalTrials.gov with Relypsa, Inc. as lead sponsor.

NCT NCT02033317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02033317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients
Lead sponsor
Relypsa, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2008
Completion date
December 31, 2008
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia